MDM2 and melanoma: Co-administration of MDM2 inhibitor was beneficial in melanoma cells resistant to CDK4/6 inhibition, characterised by abnormal PI3K/AKT (phosphoinositide 3-kinase/protein kinase B) signalling, and CDK4/6 inhibition upregulated cyclin D1 that sequestered p21.